vs
Side-by-side financial comparison of American Homes 4 Rent (AMH) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
American Homes 4 Rent is the larger business by last-quarter revenue ($455.0M vs $281.3M, roughly 1.6× Guardant Health, Inc.). American Homes 4 Rent runs the higher net margin — 31.7% vs -45.7%, a 77.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 4.2%). American Homes 4 Rent produced more free cash flow last quarter ($823.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 3.6%).
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
AMH vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $455.0M | $281.3M |
| Net Profit | $144.3M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | -43.0% |
| Net Margin | 31.7% | -45.7% |
| Revenue YoY | 4.2% | 39.4% |
| Net Profit YoY | 0.3% | -15.8% |
| EPS (diluted) | $0.33 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $455.0M | $281.3M | ||
| Q3 25 | $478.5M | $265.2M | ||
| Q2 25 | $457.5M | $232.1M | ||
| Q1 25 | $459.3M | $203.5M | ||
| Q4 24 | $436.6M | $201.8M | ||
| Q3 24 | $445.1M | $191.5M | ||
| Q2 24 | $423.5M | $177.2M | ||
| Q1 24 | $423.6M | $168.5M |
| Q4 25 | $144.3M | $-128.5M | ||
| Q3 25 | $116.8M | $-92.7M | ||
| Q2 25 | $123.6M | $-99.9M | ||
| Q1 25 | $128.7M | $-95.2M | ||
| Q4 24 | $143.9M | $-111.0M | ||
| Q3 24 | $87.6M | $-107.8M | ||
| Q2 24 | $108.5M | $-102.6M | ||
| Q1 24 | $128.1M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | — | -37.3% | ||
| Q2 25 | — | -45.9% | ||
| Q1 25 | — | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | — | -61.3% | ||
| Q2 24 | — | -56.8% | ||
| Q1 24 | — | -59.2% |
| Q4 25 | 31.7% | -45.7% | ||
| Q3 25 | 24.4% | -35.0% | ||
| Q2 25 | 27.0% | -43.0% | ||
| Q1 25 | 28.0% | -46.8% | ||
| Q4 24 | 33.0% | -55.0% | ||
| Q3 24 | 19.7% | -56.3% | ||
| Q2 24 | 25.6% | -57.9% | ||
| Q1 24 | 30.2% | -68.2% |
| Q4 25 | $0.33 | $-1.01 | ||
| Q3 25 | $0.27 | $-0.74 | ||
| Q2 25 | $0.28 | $-0.80 | ||
| Q1 25 | $0.30 | $-0.77 | ||
| Q4 24 | $0.33 | $-0.90 | ||
| Q3 24 | $0.20 | $-0.88 | ||
| Q2 24 | $0.25 | $-0.84 | ||
| Q1 24 | $0.30 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.5M | $378.2M |
| Total DebtLower is stronger | $5.1B | $1.5B |
| Stockholders' EquityBook value | $7.0B | $-99.3M |
| Total Assets | $13.2B | $2.0B |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.5M | $378.2M | ||
| Q3 25 | $45.6M | $580.0M | ||
| Q2 25 | $323.3M | $629.1M | ||
| Q1 25 | $69.7M | $698.6M | ||
| Q4 24 | $199.4M | $525.5M | ||
| Q3 24 | $162.5M | $585.0M | ||
| Q2 24 | $718.4M | $933.7M | ||
| Q1 24 | $124.8M | $1.0B |
| Q4 25 | $5.1B | $1.5B | ||
| Q3 25 | $4.8B | $1.1B | ||
| Q2 25 | $5.2B | $1.1B | ||
| Q1 25 | $4.9B | $1.1B | ||
| Q4 24 | $5.0B | $1.1B | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $5.0B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $7.0B | $-99.3M | ||
| Q3 25 | $7.2B | $-354.5M | ||
| Q2 25 | $7.2B | $-305.5M | ||
| Q1 25 | $7.2B | $-250.8M | ||
| Q4 24 | $7.2B | $-139.6M | ||
| Q3 24 | $7.0B | $-60.1M | ||
| Q2 24 | $7.0B | $-1.6M | ||
| Q1 24 | $7.0B | $68.3M |
| Q4 25 | $13.2B | $2.0B | ||
| Q3 25 | $13.3B | $1.3B | ||
| Q2 25 | $13.6B | $1.3B | ||
| Q1 25 | $13.3B | $1.3B | ||
| Q4 24 | $13.4B | $1.5B | ||
| Q3 24 | $12.8B | $1.5B | ||
| Q2 24 | $13.3B | $1.6B | ||
| Q1 24 | $12.8B | $1.7B |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.64× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $864.3M | $-26.4M |
| Free Cash FlowOCF − Capex | $823.7M | $-54.2M |
| FCF MarginFCF / Revenue | 181.0% | -19.3% |
| Capex IntensityCapex / Revenue | 8.9% | 9.9% |
| Cash ConversionOCF / Net Profit | 5.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $864.3M | $-26.4M | ||
| Q3 25 | $223.3M | $-35.4M | ||
| Q2 25 | $271.9M | $-60.3M | ||
| Q1 25 | $223.4M | $-62.7M | ||
| Q4 24 | $811.5M | $-64.5M | ||
| Q3 24 | $233.6M | $-51.1M | ||
| Q2 24 | $274.0M | $-94.0M | ||
| Q1 24 | $201.8M | $-30.3M |
| Q4 25 | $823.7M | $-54.2M | ||
| Q3 25 | $214.5M | $-45.8M | ||
| Q2 25 | $257.7M | $-65.9M | ||
| Q1 25 | $215.9M | $-67.1M | ||
| Q4 24 | $777.5M | $-83.4M | ||
| Q3 24 | $225.3M | $-55.3M | ||
| Q2 24 | $263.3M | $-99.1M | ||
| Q1 24 | $191.0M | $-37.2M |
| Q4 25 | 181.0% | -19.3% | ||
| Q3 25 | 44.8% | -17.3% | ||
| Q2 25 | 56.3% | -28.4% | ||
| Q1 25 | 47.0% | -33.0% | ||
| Q4 24 | 178.1% | -41.3% | ||
| Q3 24 | 50.6% | -28.9% | ||
| Q2 24 | 62.2% | -55.9% | ||
| Q1 24 | 45.1% | -22.1% |
| Q4 25 | 8.9% | 9.9% | ||
| Q3 25 | 1.8% | 3.9% | ||
| Q2 25 | 3.1% | 2.4% | ||
| Q1 25 | 1.6% | 2.2% | ||
| Q4 24 | 7.8% | 9.4% | ||
| Q3 24 | 1.9% | 2.2% | ||
| Q2 24 | 2.5% | 2.9% | ||
| Q1 24 | 2.6% | 4.1% |
| Q4 25 | 5.99× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 2.20× | — | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 5.64× | — | ||
| Q3 24 | 2.67× | — | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | 1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMH
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
